Forget cutting carbs, chugging kefir, or dodging low-fat or full-fat meals (depending on your guru of choice). This scientist wants us to strip it all back to basics: calories in, calories out.
Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...